Difference between revisions of "Ferumoxytol (Feraheme)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.<ref name="insert">[http://www.feraheme.com/pdfs/Feraheme_Full_Prescribing_Information_2015.pdf Ferumoxytol (Feraheme) package insert]</ref><ref>[[Media:Ferumoxytol.pdf | Ferumoxytol (Feraheme) package insert (locally hosted backup)]]</ref><ref>[http://www.amagpharma.com/products/feraheme/ Feraheme manufacturer's website]</ref>
+
Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b Ferumoxytol (Feraheme) package insert]</ref><ref>[[:File:Ferumoxytol.pdf | Ferumoxytol (Feraheme) package insert (locally hosted backup)]]</ref><ref>[https://www.feraheme.com/ Feraheme manufacturer's website]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
Line 7: Line 7:
  
 
==Patient drug information==
 
==Patient drug information==
*[http://www.feraheme.com/pdfs/Feraheme_Patient_Information_2015.pdf Ferumoxytol (Feraheme) patient drug information (AMAG Pharmaceuticals)]<ref>[http://www.feraheme.com/pdfs/Feraheme_Patient_Information_2015.pdf Ferumoxytol (Feraheme) patient drug information (AMAG Pharmaceuticals)]</ref>
+
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b Ferumoxytol (Feraheme) patient drug information]<ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b Ferumoxytol (Feraheme) patient drug information]</ref>
 
*[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
*6/30/2009: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf Initial FDA approval] "for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD)."
+
*2009-06-30: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf Initial approval] for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).
  
 
==Also known as==
 
==Also known as==
Line 22: Line 22:
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Hematology medications]]
 
[[Category:Hematology medications]]
[[Category:Iron]]
+
[[Category:Iron replacement]]
[[Category:Drugs FDA approved in 2009]]
+
[[Category:FDA approved in 2009]]

Latest revision as of 09:39, 1 July 2023

General information

Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 2009-06-30: Initial approval for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).

Also known as

  • Brand name: Feraheme

References